About: Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.73 (-2.10%)
IMRX NASDAQ Immuneering Corp
Immuneering Corp share price
Atividade de preço de IMRX
Último preço
$ 3,670
Variação (24h)
-0,14 USD (3,67%)
Volume
492.20K
Volume (média 4 sem.)
-
Abertura
$ 3,78
Variação do dia
$ 3,59 - $ 3,78
Fechamento anterior
$ 3,81
Último negócio
23 Oct, 6:25 pm GMT+0
Atrasado
23 Oct, 6:25 pm GMT+0
IMRX price performance
Atrasado
23 Oct, 6:25 pm GMT+0
quote.marketSignals